🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Dogwood Therapeutics faces potential Nasdaq delisting

EditorLina Guerrero
Published 11/21/2024, 12:42 PM
DWTX
-

Dogwood Therapeutics, Inc., a pharmaceutical company, has been notified by Nasdaq that its stockholders' equity falls short of the exchange's minimum requirement, putting its listing at risk. The notice, received on November 15, 2024, indicates that the company's equity is below the required $2.5 million threshold according to Nasdaq Listing Rule 5550(b)(1), based on the September 30, 2024, Quarterly Report.

The shortfall in equity occurred despite the company's recent acquisition of Pharmagesic (Holdings) Inc. on October 7, 2024. The notification also pointed out that Dogwood Therapeutics does not meet alternative compliance standards related to the market value of listed securities or net income from continuing operations.

Dogwood Therapeutics' common stock continues to trade on the Nasdaq Capital Market as the notice does not immediately impact its listing status. The company has until December 30, 2024, to submit a compliance plan to Nasdaq. If the plan is accepted, Nasdaq could grant up to 180 days for Dogwood to demonstrate compliance. In the event of non-acceptance, the company can appeal to a Nasdaq Hearings Panel.

The company has expressed confidence in its ability to regain compliance and intends to submit a plan within the required timeframe. However, there is no guarantee that Nasdaq will accept the compliance plan or that Dogwood Therapeutics will be able to meet the listing rule in the future.

In other recent news, Dogwood Therapeutics, previously known as Virios Therapeutics, has announced its compliance with Nasdaq's minimum bid price requirement. This development follows the company's merger with Wex Pharmaceuticals and Sealbond Limited, both affiliates of CK Life Sciences. The merger has led to the advancement of three primary assets: Halneuron®, IMC-1, and IMC-2. In response to these developments, H.C. Wainwright adjusted its stock price target for the company.

The company is expecting to release top-line results from a phase 2a study of its drug candidate IMC-2 for the treatment of Long-COVID soon. Moreover, interim data from a Phase 2 study on chemotherapy-induced neuropathic pain (CINP) using Halneuron®, is anticipated in the second half of 2025.

InvestingPro Insights

Recent InvestingPro data paints a challenging picture for Dogwood Therapeutics, aligning with the company's Nasdaq listing concerns. The company's market capitalization stands at a mere $3.24 million, precariously close to the $2.5 million stockholders' equity threshold required by Nasdaq. This low valuation is reflected in the stock's performance, with InvestingPro data showing a staggering 85.75% price decline over the past year and an 83.1% drop year-to-date.

Two key InvestingPro Tips shed light on Dogwood's financial situation. Firstly, the company "holds more cash than debt on its balance sheet," which could be a positive factor in its efforts to regain compliance. However, the tip that Dogwood "suffers from weak gross profit margins" underscores the operational challenges it faces.

These insights, along with 11 additional tips available on InvestingPro, provide a comprehensive view of Dogwood's financial health and market position. For investors closely following Dogwood's compliance efforts, InvestingPro offers valuable data to inform decision-making during this critical period.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.